drugset
drugset / Trial / NCT05080621

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

NCT05080621 ↗

Phase 1/2 Withdrawn Deciphera Pharmaceuticals, LLC
Non-randomizedSequentialOpen-labelTreatment

Summary

Multicenter, open-label Phase 1b/2 study of ripretinib in combination with binimetinib in patients with gastrointestinal stromal tumor (GIST). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2).

Timeline

Start
2021-11
Primary completion
2025-11
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Binimetinib Small molecule 15 mg —
Subject Ripretinib Small molecule 50 mg —

Indications

gastrointestinal stromal tumor